Identification of Disease Markers in Human Cerebrospinal Fluid Using Lipidomic and Proteomic Methods (original) (raw)
Related papers
Cerebrospinal Fluid Profile of Lipid Mediators In Alzheimer’s Disease
2021
Background: Alzheimer's disease (AD) develops into dementia over a period of several years, during which subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) are used as intermediary diagnoses of increasing severity. Chronic neuroinflammation resulting from insufficient resolution is involved in the pathogenesis of AD and is associated with cognitive impairment. Specialized pro-resolving lipid mediators (LMs) that promote the resolution of inflammation may be valuable markers in AD diagnosis and as therapeutic targets.Methods: Liquid chromatography-tandem mass spectrometry was used to analyze pro-resolving and pro-inflammatory LMs in cerebrospinal fluid (CSF) from patients with cognitive impairment ranging from subjective impairment to a diagnosis of AD, and correlated to cognition, CSF tau and β-amyloid (Aβ), and an inflammation biomarker (YKL-40). Results: RvD4, neuroprotectin D1, MaR1, and RvE4 were lower in AD and/or MCI compared to SCI. The pro-inflamma...
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.